Outcome | Bridging therapy (N=92) | No bridging therapy (N=143) | P value |
ORR | 79.4% | 88.8% | 0.047 |
CR rate | 63.0% | 65.7% | 0.674 |
Median OS (months) | 22.9 | Not reached | 0.005 |
Median PFS (months) | 6.03 | Not reached | 0.039 |
CRS (all grades) | 76.1% | 79.0% | 0.597 |
CRS (grade 3+) | 4.4% | 7.0% | 0.574 |
ICANS (all grades) | 54.4% | 52.5% | 0.776 |
ICANS (grade 3+) | 20.7% | 23.1% | 0.748 |
CR, complete response; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.